Mouse Anti-Bpifb1 Recombinant Antibody (CBT3484) (V2LY-0625-LY2799)

Jiang, X., Deng, X., Wang, J., Mo, Y., Shi, L., Wei, F., ... & Zeng, Z. (2021). BPIFB1 Inhibits Vasculogenic Mimicry Via Downregulation Of GLUT1-Mediated H3K27 Acetylation In Nasopharyngeal Carcinoma.

Li, J., Xu, P., Wang, L., Feng, M., Chen, D., Yu, X., & Lu, Y. (2020). Molecular biology of BPIFB1 and its advances in disease. Annals of translational medicine, 8(10).

Xu, Y., Tao, Z., Jiang, Y., Liu, T., & Xiang, Y. (2019). Overexpression of BPIFB1 promotes apoptosis and inhibits proliferation via the MEK/ERK signal pathway in nasopharyngeal carcinoma. International journal of clinical and experimental pathology, 12(1), 356.

De Smet, E. G., Seys, L. J., Verhamme, F. M., Vanaudenaerde, B. M., Brusselle, G. G., Bingle, C. D., & Bracke, K. R. (2018). Association of innate defense proteins BPIFA1 and BPIFB1 with disease severity in COPD. International journal of chronic obstructive pulmonary disease, 13, 11.

Wei, F., Wu, Y., Tang, L., He, Y., Shi, L., Xiong, F., ... & Zeng, Z. (2018). BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM. British journal of cancer, 118(2), 233-247.

Wei, F., Tang, L., He, Y., Wu, Y., Shi, L., Xiong, F., ... & Zeng, Z. (2018). BPIFB1 (LPLUNC1) inhibits radioresistance in nasopharyngeal carcinoma by inhibiting VTN expression. Cell death & disease, 9(4), 1-12.

Wei, F., Wu, Y., Tang, L., He, Y., Shi, L., Xiong, F., ... & Xiang, B. (2017). BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma through interaction with VTN and VIM. Br J Cancer.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols